RekrutujeFaza III
Badanie fazy III leku guselkumab i JNJ-4804
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Badane leki: guselkumabJNJ-4804
+23
+23Choroba Leśniowskiego-Crohna: badania kliniczne, Kraków
Badania kliniczne w obszarze: choroba Leśniowskiego-Crohna, prowadzone w ośrodkach w mieście Kraków. Zobacz też wszystkie badania: choroba Leśniowskiego-Crohna w Polsce.
22 badania: 22 rekrutują.
Lista badań
RekrutujeFaza III
Badanie fazy III leku guselkumab i risankizumab
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Badane leki: guselkumabrisankizumab
+9
+9RekrutujeFaza II
Badanie fazy II leku LY3074828 i LY4395089
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Badane leki: LY3074828LY4395089
+2
+2RekrutujeFaza II
Badanie fazy II leku LY4395089 i mirikizumab
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Badane leki: LY4395089mirikizumabLY3074828+2
+2RekrutujeFaza II/III
Badanie fazy II/III leku icotrokinra
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Badane leki: icotrokinra+20
+20RekrutujeFaza III
Badanie fazy III leku SAR447189
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Badane leki: SAR447189
+33
+33RekrutujeFaza III
Badanie fazy III leku SAR447189
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Badane leki: SAR447189+34
+34RekrutujeFaza II
Badanie fazy II leku SAR442970
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
Badane leki: SAR442970
+4
+4RekrutujeFaza III
Badanie fazy III leku RO7790121 i RVT-3101
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Badane leki: RO7790121RVT-3101+29
+29RekrutujeFaza III
Badanie fazy III leku RO7790121 i RVT-3101
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Badane leki: RO7790121RVT-3101+33
+33RekrutujeFaza II/III
Badanie kliniczne fazy II/III
A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's disease.
RekrutujeFaza II/III
Badanie fazy II/III leku budesonide
Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum
Badane leki: budesonide
RekrutujeFaza III
Badanie fazy III leku MK-7240
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Badane leki: MK-7240
+22
+22RekrutujeFaza II
Badanie fazy II leku ABBV-382 i risankizumab
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Badane leki: ABBV-382risankizumabABBV-8736lutikizumab
+26
+26RekrutujeFaza II
Badanie fazy II leku ABX464
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Badane leki: ABX464
+4
+4RekrutujeFaza III
Badanie fazy III leku MK-7240 i PRA023
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Badane leki: MK-7240PRA023+39
+39RekrutujeFaza III
Badanie fazy III leku vedolizumab i MLN0002
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Badane leki: vedolizumabMLN0002
+8
+8RekrutujeFaza III/IV
Badanie fazy III/IV leku upadacitinib i vedolizumab
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Badane leki: upadacitinibvedolizumab+18
+18RekrutujeFaza II
Badanie fazy II leku MORF-057
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Badane leki: MORF-057
+20
+20RekrutujeFaza III
Badanie fazy III leku vedolizumab i MLN0002
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Badane leki: vedolizumabMLN0002+9
+9RekrutujeFaza III
Badanie fazy III leku prednisone i vedolizumab
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Badane leki: prednisonevedolizumabMLN0002
+10
+10RekrutujeFaza III
Badanie fazy III leku prednisone i budesonide
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Badane leki: prednisonebudesonidevedolizumabMLN0002+10
+10Choroba Leśniowskiego-Crohna: inne miasta
Nie wiesz, które badanie jest dla Ciebie?
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Zadzwoń do naszego specjalisty+48 664 930 800pon-pt: 9:00 - 18:00
Wolisz, żebyśmy oddzwonili? Zostaw numer
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.